IL265342B2 - Use of pridofidine for the treatment of Rett syndrome - Google Patents
Use of pridofidine for the treatment of Rett syndromeInfo
- Publication number
- IL265342B2 IL265342B2 IL265342A IL26534219A IL265342B2 IL 265342 B2 IL265342 B2 IL 265342B2 IL 265342 A IL265342 A IL 265342A IL 26534219 A IL26534219 A IL 26534219A IL 265342 B2 IL265342 B2 IL 265342B2
- Authority
- IL
- Israel
- Prior art keywords
- pridopidine
- composition
- subject
- bdnf
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395854P | 2016-09-16 | 2016-09-16 | |
| PCT/US2017/051803 WO2018053280A1 (en) | 2016-09-16 | 2017-09-15 | Use of pridopidine for treating rett syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL265342A IL265342A (en) | 2019-05-30 |
| IL265342B2 true IL265342B2 (en) | 2023-06-01 |
Family
ID=61619744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL265342A IL265342B2 (en) | 2016-09-16 | 2019-03-13 | Use of pridofidine for the treatment of Rett syndrome |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3512506B1 (enExample) |
| JP (1) | JP6977029B2 (enExample) |
| CN (1) | CN109982686A (enExample) |
| AU (1) | AU2017326013B2 (enExample) |
| BR (1) | BR112019005040A2 (enExample) |
| CA (1) | CA3036984C (enExample) |
| DK (2) | DK3512506T3 (enExample) |
| ES (2) | ES2986807T3 (enExample) |
| HU (1) | HUE058314T2 (enExample) |
| IL (1) | IL265342B2 (enExample) |
| MX (1) | MX388845B (enExample) |
| PL (2) | PL3512506T3 (enExample) |
| WO (1) | WO2018053280A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| BR112019003731A2 (pt) | 2016-08-24 | 2019-07-16 | Prilenia Therapeutics Dev Ltd | aplicação de pridopidina para tratamento de distonias |
| JP6912574B2 (ja) | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2986807T3 (es) | 2016-09-16 | 2024-11-12 | Prilenia Neurotherapeutics Ltd | Pridopidina para su uso en el tratamiento del síndrome de Rett |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| US12357624B2 (en) | 2019-02-04 | 2025-07-15 | Prilenia Neurotherapeutics Ltd. | Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001046145A1 (en) * | 1999-12-22 | 2001-06-28 | A. Carlsson Research Ab | New modulators of dopamine neurotransmission |
| WO2013086425A1 (en) * | 2011-12-08 | 2013-06-13 | IVAX International GmbH | The hydrobromide salt of pridopidine |
| WO2015112601A1 (en) * | 2014-01-22 | 2015-07-30 | IVAX International GmbH | Modified release formulations of pridopidine |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005293754B2 (en) | 2004-10-13 | 2011-07-21 | Teva Pharmaceuticals International Gmbh | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| EA027748B1 (ru) | 2012-04-04 | 2017-08-31 | Тева Фармасьютикалз Интернэшнл Гмбх | Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения |
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| EP3590512A1 (en) * | 2015-02-25 | 2020-01-08 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat epilepsy |
| ES2986807T3 (es) | 2016-09-16 | 2024-11-12 | Prilenia Neurotherapeutics Ltd | Pridopidina para su uso en el tratamiento del síndrome de Rett |
-
2017
- 2017-09-15 ES ES22150695T patent/ES2986807T3/es active Active
- 2017-09-15 ES ES17851614T patent/ES2909557T3/es active Active
- 2017-09-15 DK DK17851614.2T patent/DK3512506T3/da active
- 2017-09-15 BR BR112019005040A patent/BR112019005040A2/pt not_active Application Discontinuation
- 2017-09-15 MX MX2019003069A patent/MX388845B/es unknown
- 2017-09-15 HU HUE17851614A patent/HUE058314T2/hu unknown
- 2017-09-15 CA CA3036984A patent/CA3036984C/en active Active
- 2017-09-15 DK DK22150695.9T patent/DK4005570T3/da active
- 2017-09-15 EP EP17851614.2A patent/EP3512506B1/en active Active
- 2017-09-15 PL PL17851614T patent/PL3512506T3/pl unknown
- 2017-09-15 JP JP2019514217A patent/JP6977029B2/ja active Active
- 2017-09-15 AU AU2017326013A patent/AU2017326013B2/en active Active
- 2017-09-15 EP EP22150695.9A patent/EP4005570B1/en active Active
- 2017-09-15 CN CN201780071045.XA patent/CN109982686A/zh active Pending
- 2017-09-15 WO PCT/US2017/051803 patent/WO2018053280A1/en not_active Ceased
- 2017-09-15 PL PL22150695.9T patent/PL4005570T3/pl unknown
-
2019
- 2019-03-13 IL IL265342A patent/IL265342B2/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001046145A1 (en) * | 1999-12-22 | 2001-06-28 | A. Carlsson Research Ab | New modulators of dopamine neurotransmission |
| WO2013086425A1 (en) * | 2011-12-08 | 2013-06-13 | IVAX International GmbH | The hydrobromide salt of pridopidine |
| WO2015112601A1 (en) * | 2014-01-22 | 2015-07-30 | IVAX International GmbH | Modified release formulations of pridopidine |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
Non-Patent Citations (1)
| Title |
|---|
| LI W ET AL., BDNF DEREGULATION IN RETT SYNDROME, 15 April 2013 (2013-04-15) * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019005040A2 (pt) | 2019-07-16 |
| AU2017326013B2 (en) | 2020-12-24 |
| MX388845B (es) | 2025-03-20 |
| EP3512506A4 (en) | 2020-05-27 |
| CA3036984A1 (en) | 2018-03-22 |
| EP3512506A1 (en) | 2019-07-24 |
| CA3036984C (en) | 2023-07-18 |
| ES2986807T3 (es) | 2024-11-12 |
| AU2017326013A1 (en) | 2019-04-11 |
| JP2019532926A (ja) | 2019-11-14 |
| EP4005570B1 (en) | 2024-05-15 |
| DK4005570T3 (da) | 2024-08-19 |
| WO2018053280A1 (en) | 2018-03-22 |
| CN109982686A (zh) | 2019-07-05 |
| IL265342A (en) | 2019-05-30 |
| HUE058314T2 (hu) | 2022-07-28 |
| EP4005570A1 (en) | 2022-06-01 |
| ES2909557T3 (es) | 2022-05-09 |
| PL4005570T3 (pl) | 2024-09-23 |
| PL3512506T3 (pl) | 2022-05-30 |
| EP3512506B1 (en) | 2022-01-26 |
| JP6977029B2 (ja) | 2021-12-08 |
| MX2019003069A (es) | 2019-09-02 |
| DK3512506T3 (da) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017326013B2 (en) | Use of pridopidine for treating Rett syndrome | |
| JP5875191B2 (ja) | Ｃｍｔ及び関連障害を処置するための新たな組成物 | |
| US11221329B2 (en) | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity | |
| AU2018342072B2 (en) | Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations | |
| US20190247333A1 (en) | Method of reduction in convulsive seizure frequency | |
| JP2010510314A (ja) | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 | |
| EP3887481A1 (en) | A method of treating refractory epilepsy syndromes using fenfluramine enantiomers | |
| KR20160037169A (ko) | 레트 증후군 및 그를 위한 치료 | |
| WO2019067413A1 (en) | USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS | |
| US20230117508A1 (en) | Enhancement of camp signaling as a combination drug strategy for the treatment of psychiatric and neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists | |
| US20240398778A1 (en) | Use of pridopidine for treating rett syndrome | |
| JP7744419B2 (ja) | レット症候群を治療するためのプリドピジンまたはその類似体の使用 | |
| HK40009961B (en) | Use of pridopidine for treating rett syndrome | |
| CN108601772A (zh) | 用于治疗tdp-43蛋白质病的他克莫司 |